thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
=== 1920s === In 1928, British Scientist Alexander Fleming discovered the first antibiotic penicillin. This was a huge breakthrough in biomedical science because it allowed for the treatment of bacterial infections. In 1926, the first artificial pacemaker was made by Australian physician Dr. Mark C. Lidwell. This portable machine was plugged into a lighting point. One pole was applied to a skin pad soaked with strong salt solution, while the other consisted of a needle insulated up to the point and was plunged into the appropriate cardiac chamber and the machine started. A switch was incorporated to change the polarity. The pacemaker rate ranged from about 80 to 120 pulses per minute and the voltage also variable from 1.5 to 120 volts.
7.46 mg dihydrocodeine as co-dydramol 7.46/500 (e.g. in the branded product Paramol). 10 mg dihydrocodeine as co-dydramol 10/500, this is also the preparation to be dispensed if no strength is specified on a prescription. 20 mg dihydrocodeine as co-dydramol 20/500 (e.g. branded products Paracod 500/20 and Remedeine). 30 mg dihydrocodeine as co-dydramol 30/500 (e.g. branded products Paracod 500/30 and Remedeine Forte).
== Use and effects == The drug produces similar autonomic and psychoactive effects as LSD in humans, although its hallucinogenic effects are less pronounced. It has been found to possess about one-sixth to one-eighth (i.e., ~15% overall) of the potency of LSD in inducing mydriasis (pupil dilation) and psychedelic effects, respectively, in humans. More specifically, 2,3-dihydro-LSD is psychedelic at doses of 3.0 to 4.5 μg/kg (210–315 μg for a 70-kg person), while LSD is hallucinogenic at doses of 0.5 to 1.0 μg/kg (35–70 μg for a 70-kg person). In addition to its greatly reduced potency compared to LSD, 2,3-dihydro-LSD has a delayed onset and time to peak effects relative to LSD. The duration of 2,3-dihydro-LSD was roughly 8 to 12 hours and was longer than that of LSD (which had a duration of about 7 hours in the study) as well.
Sources: en.wikipedia.org
The Mojave rattlesnake is widely regarded as producing one of the most toxic snake venoms in the New World, based on LD50 studies in laboratory mice. Their potent venom is the result of a presynaptic neurotoxin composed of two distinct peptide subunits. The basic subunit (a phospholipase A2) is mildly toxic and apparently rather common in North American rattlesnake venoms. The less common acidic subunit is not toxic by itself, but in combination with the basic subunit, produces the potent neurotoxin called "Mojave toxin". Nearly identical neurotoxins have been discovered in five North American rattlesnake species besides the Mojave rattlesnake. However, not all populations express both subunits. The venom of many Mojave rattlesnakes from south-central Arizona lacks the acidic subunit and has been designated "venom B", while Mojave rattlesnakes tested from all other areas express both subunits and have been designated "venom A" populations.
== History == In the late 600s and into the 700s, St. Bede lived as a monk at the monastery of St. Peter and of St. Paul writing histories of the Early Middle Ages including the Ecclesiastical History of the English People. Roughly 150 years ago, in the village of Marsden in South Shields, Souter Lighthouse was built, the first electric structure of this type. The Local Government Act 1888 constituted Newcastle upon Tyne, Gateshead and Sunderland as county boroughs (Newcastle had "county corporate" status as the "County and Town of Newcastle upon Tyne" since 1400). Tynemouth joined them in 1904. Between the county boroughs, various other settlements also formed part of the administrative counties of Durham and of Northumberland. The need to reform local government on Tyneside was recognised by the government as early as 1935, when a Royal Commission to Investigate the Conditions of Local Government on Tyneside was appointed. The three commissioners were to:
=== Rice and seafood === It's estimated that an average adult in the United States consumes 3.2 μg/day of arsenic, with a range of 1–20 μg/day. Estimates for children were similar. Food also contains many organic arsenic compounds. A wide range of arsenic containing compounds have been found in food,although arsenic compounds may range significantly in toxicity. Seafood is a common source of organic arsenic in the form of arsenobetaine. There is evidence indicating that arsenocholine, which can be found in some food sources, is non-toxic. Arsenosugars are present in some forms of seafood and been shown through in vitro studies to be significantly less toxic than both inorganic arsenic and trivalent methylated arsenic metabolites. It has been found that rice is particularly susceptible to the accumulation of arsenic from soil. Rice grown in the United States has an average 260 ppb of arsenic, but U.S. arsenic intake remains far below World Health Organization-recommended limits. China has set a standard for arsenic limits in food (150 ppb), as levels in rice exceed those in water.
Related cyclopropenium cations are produced in the regeneration of the 1,1-dichlorocyclopropenes from the cyclopropenones. The cyclopropenium chlorides have been applied to peptide bond formation. For example, in the figure below, reacting a boc-protected amino acid with an unprotected amino acid in the presence of the cyclopropenium ion allows the formation of a peptide bond via acid chloride formation followed by nucleophilic substitution with the unprotected amino acid.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.